Voyager Therapeutics Inc. (Nasdaq: VYGR) entered an exclusive strategic collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) to develop and commercialize vectorized antibodies to treat Alzheimer's disease. Shares of Voyager Therapeutics leaped $4.30 to close at $23.66 while AbbVie stock slipped 62 cents to close at $117.98.
Voyager Therapeutics enters agreement with AbbVie
February 20, 2018 at 18:13 PM EST